Explanipedia

Characterisation of the Novel HLA‐DRB4*01:193 Allele by Sequencing‐Based Typing Open

Lucie Blandin, Élodie Wojciechowski, Mamy Ralazamahaleo, Richard Lemal, Paul Rouzaire · 2025

HLA‐DRB4*01:193 differs from HLA‐DRB4*01:03:01:01 by one nucleotide substitution in codon 166 in exon 3.

Characterisation of the Novel HLA‐DRB5*02:02:05 Allele by Sequencing‐Based Typing Open

Lucie Blandin, Mamy Ralazamahaleo, Marine Cargou, Richard Lemal, Paul Rouzaire · 2024

HLA‐DRB5*02:02:05 differs from HLA‐DRB5*02:02:01 by one nucleotide substitution in codon 134 in exon 3.

Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin Open

Maël Heiblig, C. Gourguechon, Philippe Guilpain, C. Bulaï Livideanu, Stéphane Barete , et al. · 2024

Advanced systemic mastocytosis (AdvSM) encompasses heterogeneous mastocytosis subtypes and is associated with poor outcomes. Although midostaurin was the first tyrosine kinase inhibitor to be approved for AdvSM patients, long‐lasting respo…

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis Open

Julien Rossignol, Sophie Georgin‐Lavialle, Danielle Canioni, Omer Beganovic, Chantal Brouzes , et al. · 2024

Not available.

Daratumumab treatment in six highly sensitised solid organ transplant recipients: A case series and literature review Open

Richard Lemal, Lucie Blandin, Charlotte Uro‐Coste, Carole Philipponnet, Étienne Geoffroy , et al. · 2024

We report data on six kidney or heart recipients who were administered daratumumab to treat or prevent antibody‐mediated rejection (ABMR). To date, data are scarce concerning the use of daratumumab in solid organ transplantation and most r…

Histological characterization of liver involvement in systemic mastocytosis Open

Julien Rossignol, Danielle Canioni, Achille Aouba, C. Bulaï Livideanu, Stéphane Barète , et al. · 2024

Background and Aims Systemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been marginally described and accurate histological classification is critical, given the…

Impact of Calcineurin Inhibitor-Based Immunosuppression Maintenance During the Dialysis Period After Kidney Transplant Failure on the Next Kidney Graft Outcome: A Retrospective Multicenter Study With Propensity Score Analysis Open

Juliette Noelle, Valentin Mayet, Céline Lambert, Lionel Couzi, Bertrand Chauveau , et al. · 2023

The impact of immunosuppressive therapy (IS) strategies after kidney transplant failure (KTF) on potential future new grafts is poorly established. We assessed the potential benefit of calcineurin inhibitor (CNI)-based IS maintenance throu…

Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes Open

Laura Polivka, Marine Madrange, C. Bulaï Livideanu, Stéphane Barete, Thomas Ballul , et al. · 2023

Issue Information Open

Steven G. E. Marsh, Katharina Fleischhauer, John Germany, Sebastiaan Hammond, The Heidt , et al. · 2022

COVID‐19 systematic screening of asymptomatic haematopoietic stem cell donors: Less if often more Open

Lucie Blandin, Elise Tolmer, Éric Hermet, Aurélie Ravinet, Amélie Brebion , et al. · 2022

From COVID pandemic spread until now, many HSCT unrelated donor registries recommend as a precaution a systematic COVID‐19 testing for all donors during the precollection time. Literature is quite poor to support this systematic attitude. …

Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia? Open

Julien Labreuche, Déborah Assouan, Éric Durot, Cécile Tomowiak, Damien Roos‐Weil , et al. · 2022

In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B‐cell and T‐cell lymphomas, disease progression within 24 month…

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia Open

Richard Lemal, Stéphanie Poulain, Albane Ledoux‐Pilon, Lauren Véronèse, Andréï Tchirkov , et al. · 2022

The presence of numerous mast cells (MCs) mixed with tumor cells in the bone marrow (BM) is a hallmark of the diagnosis of Waldenström's macroglobulinemia (WM). MCs have been shown to support lymphoplasmacytic cell growth, but there is thu…

Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study Open

Fabrice Giraudet, Marie Selvy, Nicolas Kerckhove, Bruno Pereira, Fantine Barreau , et al. · 2022

Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders Open

Julien Rossignol, Amani Ouedrani, C. Bulaï Livideanu, Stéphane Barète, Louis Terriou , et al. · 2022

Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response Open

Julien Rossignol, Amani Ouedrani, C. Bulaï Livideanu, Stéphane Barète, Louis Terriou , et al. · 2021

Mast cells are key actors of innate immunity and Th2 adaptive immune response which counterbalance Th1 response, critical for anti-viral immunity. Clonal Mast Cells Activation Disorders (cMCADs) such as mastocytosis and clonal mast cells a…

Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study Open

Marie Selvy, Nicolas Kerckhove, Bruno Pereira, Fantine Barreau, Daniel P. Nguyen , et al. · 2021

Bortezomib is a pivotal drug for the management of multiple myeloma. However, bortezomib is a neurotoxic anticancer drug responsible for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with psychological distress and …

Management of Immunosuppression After Kidney Transplant Failure: Effect on Patient Sensitization Open

Marine Freist, Dominique Bertrand, É. Bailly, Céline Lambert, Paul Rouzaire , et al. · 2020

Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency Open

Hélène Coignard-Biehler, Nizar Mahlaoui, B. Pilmis, Vincent Barlogis, Pauline Brosselin , et al. · 2020

Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial Open

Olivier Tournilhac, Magali Le Garff‐Tavernier, Stéphanie Nguyen Quoc, Édouard Forcade, Patrice Chevallier , et al. · 2020

Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing CLL. Minimal Residual Disease (MRD) assessment at 12 months post-HSCT is predictive of relapse. This phase …

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 Open

Richard Lemal, Olivier Tournilhac · 2019

Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mecha…

Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS Open

Richard Lemal, Guillemette Fouquet, Louis Terriou, M. Vaes, C. Bulaï Livideanu , et al. · 2019

Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry Open

Nizar Mahlaoui, Capucine Pïcard, Perrine Bach, Laurence Costes, Virginie Courteille , et al. · 2019

Outcome and impact of post‐remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia Open

Salem Bahashwan, Cécile Moluçon‐Chabrot, Éric Hermet, Aurélie Ravinet, Aurore Dougé , et al. · 2018

International audience

Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers Open

Sylvain Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, Frédéric Peyrade, Marie‐Virginie Larcher , et al. · 2018

Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine‐based (BeEAM). The aim of this study was to evaluate th…

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO) Open

Éric Durot, Cécile Tomowiak, Anne‐Sophie Michallet, Jehan Dupuis, Bénédicte Hivert , et al. · 2017

Summary Histological transformation ( HT ) to diffuse large B‐cell lymphoma ( DLBCL ) is a rare and poorly reported complication of Waldenström macroglobulinaemia ( WM ). We performed a retrospective study of 77 WM patients with biopsy‐pro…

Bone marrow hematons: An access point to the human hematopoietic niche Open

Alexandre Janel, Juliette Berger, Céline Bourgne, Richard Lemal, Nathalie Boiret‐Dupré , et al. · 2017

To understand the complex interactions between hematopoietic stem cells and the bone marrow niche, a human experimental model is needed. Our hypothesis is that hematons are an appropriate ex vivo model of human bone marrow. We analyzed the…

AB0035 Angiopoietins: the missing link in poems syndrome? Open

Frédéric Coutant, Zeynep Baran Tatar, P-O Rouzaire, Bérangère Evrard, Annie Dosgilbert , et al. · 2017

NON‐MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA Open

Clémentine Sarkozy, Anja Mottok, Hervé Ghesquières, C. Herbeaux, Susana Ben‐Neriah , et al. · 2017

Introduction: Mediastinal grey zone lymphomas (MGZL) present an intermediate morphology between classical Hodgkin lymphoma (CHL) and primary mediastinal large B cell lymphoma (PMBCL). Cases without mediastinal involvement or non-MGZL (NMGZ…

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients Open

Anne Wanquet, Rudy Birsen, Charlotte Bonnet, Marouane Boubaya, Sylvain Choquet , et al. · 2016

Summary Central nervous system involvement ( CNS i) is a rare and poorly reported complication of chronic lymphocytic leukaemia ( CLL ). Establishing cause and effect between the CLL and the neurological symptoms remains challenging. We ha…

Telomere status in chronic lymphocytic leukemia with TP53 disruption Open

Romain Guièze, Mélanie Pagès, Lauren Véronèse, Patricia Combes, Richard Lemal , et al. · 2016

In chronic lymphocytic leukemia (CLL), telomere dysfunction is associated with poor outcomes. TP53 is involved in cellular responses to dysfunctional telomeres, and its inactivation is the strongest adverse prognostic factor for CLL. Given…

Richard Lemal YOU? Author Swipe